VEGFA and hepatocellular carcinoma: [2] On the other hand, bevacizumab is a recombinant humanized monoclonal antibody targeting VEGF (Vascular Endothelial Growth Factor), which plays a pivotal role in HCC development and progression by triggering neoangiogenesis as well as immune tolerance [3].